BASEL (dpa-AFX) - Novartis (NVS) announced Thursday that the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) in HR+/HER2- advanced br...
More From BioPortfolio on "Novartis: Phase III SOLAR-1 Trial On PI3K Inhibitor BYL719 Met Primary Goal"